Inicio
Este sitio está destinado a profesionales de la salud.

Guía sobre la fibrosis pulmonar, módulo 3: La toma de decisiones terapéuticas en condiciones de incertidumbre

Compartir

Descripción

Esta actividad cuenta con el apoyo de una subvención educativa independiente de BMS. Este programa educativo en línea se ha diseñado para profesionales sanitarios de todo el mundo, excepto del Reino Unido.

Únete al experto Corey Kershaw, doctor en Medicina, en una sesión en profundidad sobre cómo abordar el manejo del tratamiento antifibrótico y los mecanismos emergentes. En esta sesión se exploran estrategias para mitigar de forma proactiva los efectos adversos gastrointestinales, garantizar la adherencia al tratamiento e integrar las nuevas pruebas científicas en planes terapéuticos personalizados para cada paciente.

Este es el tercer módulo de un total de cuatro. Los módulos uno, dos y cuatro se pueden consultar aquí.

Puntos destacados de la sesión

  • Gestionar de forma proactiva los efectos secundarios gastrointestinales mediante estrategias antieméticas, ajustes dietéticos y reducciones de dosis respaldadas por la ficha técnica antes de interrumpir el tratamiento antifibrótico.
  • Utilizar herramientas de seguimiento domiciliario y puntuaciones de resultados comunicadas por los pacientes para realizar un seguimiento de las tendencias de adherencia y detectar precozmente los riesgos de tolerabilidad.
  • Evaluar el panorama terapéutico en expansión, incluidos los inhibidores de la PDE4B recientemente aprobados y los agentes en fase 3 de investigación (agonistas de la prostaciclina y antagonistas de LPA1).
  • Implementar sistemas de apoyo a la toma de decisiones clínicas que combinen la verificación de la idoneidad con avisos de seguimiento activo para orientar los ajustes terapéuticos.

Público destinatario

Esta actividad está dirigida a neumólogos, reumatólogos, radiólogos torácicos, patólogos, enfermeros especializados en neumología y auxiliares médicos que desempeñan un papel fundamental en el diagnóstico y el tratamiento de la FPI y la FPP. También está diseñada para médicos de cabecera, terapeutas respiratorios, farmacéuticos y otros profesionales sanitarios multidisciplinares que participan en la atención de pacientes con fibrosis pulmonar.

Profesorado

El Dr. Corey Kershaw es catedrático del Departamento de Medicina Interna, dentro de la División de Medicina Pulmonar y de Cuidados Intensivos de la UT Southwestern. Desempeña el cargo de jefe de servicios clínicos de la División de Medicina Pulmonar y de Cuidados Intensivos, así como el de director médico de la Unidad de Cuidados Intensivos Médicos y de Terapia Respiratoria del Hospital Universitario William P. Clements Jr. Cuenta con una amplia experiencia clínica en el tratamiento de afecciones pulmonares complejas y en medicina de cuidados intensivos.

Declaraciones de intereses

De conformidad con las directrices de EBAC®, todos los ponentes y moderadores que participan en este programa han declarado o señalado cualquier posible conflicto de intereses que pudiera sesgar sus presentaciones. El Comité Organizador o el director del curso es responsable de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a los asistentes antes del inicio de las actividades de formación continua.

El Dr. Corey Kershaw, ponente de esta actividad, ha revelado relaciones financieras en los últimos 36 meses con las siguientes empresas no elegibles: consultor, asesor y ponente para Boehringer Ingelheim; investigador para Avalyn Pharma, Bristol Myers Squibb, Daewoong Pharmaceutical, PureTech Health/Celea Therapeutics y United Therapeutics.

El personal de MedAll, así como los organizadores y revisores, no tienen relaciones financieras relevantes con empresas no elegibles que deban revelarse.

Información sobre la formación médica continua (FMC) de EBAC®:

Esta actividad se ha planificado y llevado a cabo de conformidad con los requisitos y políticas de acreditación de la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC).

MedAll es un proveedor acreditado por la EBAC desde 2025. La Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC) acredita programas de formación continua (FC) para la comunidad médica internacional.

Este programa está acreditado por la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC®) con 15 minutos de tiempo efectivo de formación.

De conformidad con las directrices de la EBAC, todos los ponentes y moderadores que participan en este programa han revelado o señalado posibles conflictos de intereses que podrían dar lugar a un sesgo en las presentaciones. El Comité Organizador y el director del curso son responsables de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a los asistentes antes del inicio de las actividades de formación continua.

EBAC® mantiene un acuerdo de reconocimiento mutuo de equivalencia sustantiva con el Consejo de Acreditación de Estados Unidos para la Formación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá, respectivamente.

Mediante un acuerdo entre la Junta Europea de Acreditación de la Formación Continua para Profesionales de la Salud (EBAC®) y la Asociación Médica Americana (AMA), los médicos pueden convertir los créditos de formación médica continua externa de EBAC® en créditos AMA PRA de categoría 1. La información sobre el proceso para convertir créditos EBAC® en créditos AMA se puede consultar en la página web de la AMA. Otros profesionales sanitarios pueden obtener de la AMA un certificado de participación en una actividad que da derecho a la conversión de créditos en créditos AMA PRA de Categoría 1.

El Consejo de Acreditación para la Educación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá mantienen un acuerdo de equivalencia sustantiva de los sistemas de acreditación con EBAC.

EBAC® es miembro de la Academia Internacional para la Acreditación del Desarrollo Profesional Continuo (IACPDA) y miembro asociado de la Asociación Internacional de Autoridades Reguladoras Médicas (IAMRA).

Cómo obtener su crédito de formación médica continua (FMC) de EBAC®:

Para obtener su crédito de FMC y recibir su certificado, participe en la actividad y complete la evaluación al final. Recibirá un enlace a su certificado tras completar la evaluación.

Costes de participación

La participación en este programa es gratuita.

Esta actividad de formación continua estará activa a partir del 1 de noviembre de 2026 y caducará el 30 de septiembre de 2027.

Tiempo estimado para completar esta actividad: 15 minutos

Objetivos de aprendizaje

Al finalizar esta actividad, los participantes serán capaces de:

  • Incorporar la estratificación del riesgo, las técnicas de imagen de alta resolución y la evaluación multidisciplinar para diferenciar y diagnosticar la FPI y la FPP de otras enfermedades pulmonares intersticiales de forma precoz y precisa.
  • Poner en práctica estrategias multidisciplinares de diagnóstico y tratamiento para mejorar la detección oportuna, la derivación y la atención coordinada de los pacientes con FPI.
  • Aplicar los conocimientos sobre los mecanismos de acción y la evidencia clínica a las decisiones terapéuticas, incluyendo la selección de pacientes y el momento adecuado para iniciar el tratamiento.

Comunidades similares

Ver todo

Eventos y vídeos bajo demanda similares

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

All right. Um, we're gonna move on to treatment decision under uncertainty. So we're still, um, taking care of Margaret. Margaret has now started ninitinib, and we're seeing her back, you know, uh, to talk about how she's doing with ninitinib. Look at her home spirometry at week 8. And um her home dashboard, we're gonna look at. She's, um, things are going well with her lungs, maybe not so well with other things lung adjacent, so we'll discuss that. So, week 8 on nintentinib, her home spirometry looks great. It's unchanged. That's our primary goal when we start a patient on an antifibrotic like nintentinib. However, she's having some difficulty with um some side effects. She reports nausea on most days. Um, she's missed two doses in the last week because of the side effect, and she reports a 1.5 kg weight loss since initiation after eight weeks, and I would argue that that's, that's significant, um, after only eight weeks. So we're now, we're now detecting an adherence risk. So our dashboard's advising us that perhaps we should, um, review the dose and talk to the patient. And really this is not an uncommon scenario and I, I think one of the ways to mitigate this that we've discussed is, you know, getting ahead of the side effects at least from a knowledge-based perspective because it's really the GI intolerance that leads to um discontinuation or underdosing because of dose changes of the antifibrotics and patients sometimes won't tell you this, so it's important that that this becomes Um, every patient touch point, you ask them these questions, not just how they're feeling in terms of their pulmonary symptoms, but how they're tolerating the medication because they may not bring it up. There may be an embarrassment factor, um, you know, patients want our approval and they're perhaps uncomfortable sharing that, you know, they're taking their, their doses, not every day. So, um, here's our home monitoring tab with our dashboard. Um, we identified that, uh, our patient Margaret is taking nintentinib 150 mg twice per day. She's reporting moderate GI side effects and she's missed two doses in the last week and there's our weight change. So this, this home monitoring dashboard really concept really gives us A nice snapshot of what's going on with our patient at this moment. We can see her side effects summary. We're already getting an alert that the patient is stopping in spite of apparent drug effectiveness, and again, Underdosing or discontinuation of the antifibrotics is, is really true in the real world, so we have to discuss these questions. But the nice thing about the dashboard concept is that we can monitor the patient and perhaps pick up these issues early so the patient's therapy is not only optimized but side effects are mitigated to improve adherence. So, Here's an informal poll, just hands up in the chat, um, you know, who has had a patient out there stop an anti-fibrotic because of GI GI side effects without telling you. Um, so choice A, yes, and we found out late. Choice B, yes, but we caught it early. C, not that I know of. D, I don't prescribe these antifibrotics, or E, I prefer not to say. Let's give everyone an opportunity to answer with raising your hands. OK. Very interesting results there. I think we all feel very similarly about this. All right, let's move on. So, how can we address this problem? We've spent time during our presentation with you discussing Uh, how to identify the patient problems, how to start them on therapy, but we really need to address tolerability, you know, our, our job is not done once we decide to treat a patient with an antifibrotic. So let's talk about some of the GI side effects of these antifibrotics. The first thing that we need to do is support the patient. If they're having nausea, consider an anti-emetic. If, um, are they taking the, the medicines with food? Nintendonib is so important to take with food. Um, if you really try to take it on an empty stomach, you're going to have GI side effects. So we need to review that with the patient, not just at the time of, uh, prescription, but at each subsequent visit to assess if there are any diet issues, either they're having trouble getting a full meal in Or they perhaps noticed some associations. They're having a full meal, but when they eat certain foods, the side effect is worse. Uh, could there be another medication that's a factor here, um, that's contributing to the nausea, so don't necessarily decide it's the intentative, for example, that's the problem. It could be something else. If we've tried the support route first and the patient is still having difficulty, that's the time to consider dose reduction. Nintentinib has a both 150 and 100 mg doses. Um, this is supported by the labeling that you can decrease the dose for side effects, um, to 100 mg twice per day. Um, this at least preserves, preserves the patients taking treatment and post-hoc data suggests that there is a benefit to taking the lower dose. I'm asked this question a lot at um presentations that I give. Uh, patients ask me this question, why not start the patient at the lower dose to mitigate the side effects and we really wanna optimize the dosing, optimize the benefit. The 100 mg dose really should be reserved for side effects mitigation, not, um, in order to get them to talk the dose upfront because the reality is most patients do just fine on the full dose. So you don't wanna necessarily undertreat the patient. Out of fear of side effects before you've even tried. Um, so I, I certainly urge everyone if you're gonna start someone on, on nintentinib, use the top dosing, 150 mg twice per day and reserve the lower dose if the patient's having side effects and your, um, non-pharmacological mitigation efforts such as nausea medications, addressing food, um, issues, co-medications. Try that first before looking at a dose reduction. If the patient still has trouble, then you can consider dosing, pausing, uh, the, the nice thing about these medicines, at least in my experience is the patient's struggling, if you give them a break on the medicine, the side effect generally goes away. So, you know, having a structured interruption, name the date you're gonna stop. We're going to stop. For 1 week. We're gonna stop for 2 weeks and then I want you to start again. So don't just leave it open-ended because as I said, The side effects really are dosing dependent. If you stop the medication today, very likely you will not have side effects tomorrow. So, don't leave it open-ended because we, again, we wanna optimize time on drug to maximize benefit. Perhaps after the pause and rechallenge the patient is still having trouble, then you could consider um adding, uh, either adding a new medication or switching to something else. So, for example, prophenidone is an option, but remember, in, at least in the United States and the European Union, Um, prophenidone is indicated only for IPF. So our patient has rheumatoid arthritis, so it would be an off-label use to, uh, for prophenidone and RAILD. This is not part of routine care, at least in the United States that I can speak of. You, you run into some reimbursement issues for the patients when you're using things off-label, so it requires some navigation with insurances and co-pays. Um, there are certainly ways to do it, but it's not always straightforward. And whatever you decide to do with the patient, you really need to close the loop, you know, if someone needs to call her and talk to her about this because that's, you know, yes, the dashboard concept is helpful because we can pick up things early, but we need to let the patient know that we're watching. We care, we know what's going on, and these are the things we want to try. Um. Don't make the switch before, you know, rescuing the adherence. That's a really key principle here. So if we give up on antifibrotics, we, we've helped nobody for this. So we really want to do everything we can on the current medicine before we make a switch, OK? So, tolerability tolerability management, that really is treatment also. We're rescuing adherence, we're documenting what we do and then we're gonna call the patient, closing the loop. So what else could we do? So here's some emerging um Medications for treatment of these diseases. We'll start with neuronommalast. That's the newest kid on the block. This is an oral medication. It is a PDE4B inhibitor approved uh throughout the world, um, both for IPF and for non-IPF progressive pulmonary fibrosis. So we've got two indications for this. The way, um, neuronommalast works is we have to think about what PDE4B does. PDE4B. Um, is, um, what that does is degrades cyclic AMP. In cyclic AMP we wanna think of as a fibroblast break. So we, we need cyclic AMP to cool off the activation that occurs when fibroblasts are recruited following lung injury, OK? So anything we can do to enhance cyclic AMP in this environment is helpful to mitigate the fibrosing process. By blocking PDE4B, we increase cyclic AMP. In the, uh, in the epithelial environment here which will cool off activation after fibroblast recruitment. So by preserving cyclic AMP will dampen the inflammatory cytokine release and decrease fibroblast activation. So two mechanisms. This was shown.